Immunogenicity 6 months post COVID-19 mRNA vaccination among adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors
Authors' conclusion
Although mRNA vaccines develop satisfactory immunogenicity at 1 month and 3 months post-vaccination in adolescents with JIA on TNFi, SARS-CoV-2 antibody titres decrease significantly overtime, remaining at lower levels at 6 months.
Study context
- Population
- Adolescents with JIA treated with TNFi for at least 18 months, in clinical remission, receiving two doses of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine
- Participants
- 21 adolescents
- Outcome
- IgG antibodies to SARS-CoV-2 spike protein 1 (6-month immunogenicity)
- Follow-up
- 6 months post-vaccination
Methodological detailssingle-centre, None discontinued TNFi/MTX at vaccination or during follow-up
- Single-centre
- None discontinued TNFi/MTX at vaccination or during follow-up
Main finding
As reported in the abstract
Humoral response against SARS-CoV-2 · 1, 3 and 6 months post-vaccination
- All patients developed a sustained humoral response at 1 and 3 months after vaccination
- P < 0.05
- Antibody levels decreased significantly at 6 months post-vaccination
- P < 0.01
Observational data: associations, not effects.
Further findings
Humoral response by type of JIA · 3 and 6 months post-vaccination
- No differences at 3 months
- P = 0.894
- No differences at 6 months
- P = 0.72
Immunogenicity, adalimumab vs etanercept · 3 and 6 months
- No difference at 3 months
- P = 0.387
- No difference at 6 months
- P = 0.526
Immunogenicity, TNFi monotherapy vs TNFi plus MTX · 3 and 6 months
- No difference at 3 months
- P = 0.623
- No difference at 6 months
- P = 0.885
Original publication
Immunogenicity 6 months post COVID-19 mRNA vaccination among adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors. Rheumatology (Oxford). Published 5 July 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →